OraSure Technologies Inc.
Company Snapshot
Company Overview
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The company reported revenue of $171.1 million in 2020. Under the diagnostics and testing business segment, the company has rapid diagnostics for HIV, Hepatitis C, COVID-19 and Ebola, as well as oral fluid laboratory tests for detecting various drugs of abuse.
OraSure Technologies is a global leader in infectious disease diagnostics. In July 2017, the company’s OraQuick HIV Self-Test (HIVST) received WHO prequalification.
Financial Highlights (FY 2023)
This information is available for BCC Research members only.
OraSure Technologies Inc. In News
Company's Business Segments
- Products : Cannabis Test Kit, Fentanyl+ Test Kit, Cocaine Test Kit, General Narcotics Test Kit, Heroin Test Kit, THC Test Kit, Others
- Services : Oraquick ADVANCE HIV-1/2 Rapid Antibody Test, OraQuick In-Home HIV Test, Diagnostics Direct Syphilis Health Check, OraQuick HCV Rapid Antibody Test, Inteliswab COVID-19 Rapid Test, OraQuick Ebola Rapid Antigen Test, OraSure HIV-1 Oral Specimen Collection Device
Applications/End User Industries
- Pharmaceutical
- Agriculture
- Research Community
- Biotechnology
- Diagnostics
- Life Science
- Veterinary
- Animal Health
